Project Details
Description
A Phase 2 randomized, double-blind, crossover, controlled, multi-center, subject preference study of tivozanib hydrochloride versus sunitinib in the treatment of subjects with metastatic renal cell carcinoma
| Status | Finished |
|---|---|
| Effective start/end date | 7/1/12 → 8/30/16 |
Funding
- AVEO PHARMACEUTICALS, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.